144 related articles for article (PubMed ID: 26511402)
1. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.
Lasater EA; Massi ES; Stecula A; Politi J; Tan SK; Smith CC; Gunthorpe M; Holmes JP; Chehab F; Sali A; Shah NP
Leukemia; 2016 Jun; 30(6):1405-9. PubMed ID: 26511402
[No Abstract] [Full Text] [Related]
2. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
3. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
Gibbons DL; Pricl S; Posocco P; Laurini E; Fermeglia M; Sun H; Talpaz M; Donato N; Quintás-Cardama A
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3550-5. PubMed ID: 24550512
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
6. Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
Zabriskie MS; Eide CA; Yan D; Vellore NA; Pomicter AD; Savage SL; Druker BJ; Deininger MW; O'Hare T
Leukemia; 2016 Jun; 30(6):1418-21. PubMed ID: 26582647
[No Abstract] [Full Text] [Related]
7. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
8. Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
J Hematol Oncol; 2015 Aug; 8():97. PubMed ID: 26239229
[TBL] [Abstract][Full Text] [Related]
9. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
10. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
11. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
Thomas X
Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.
Zeng P; Schmaier A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911643
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
14. Cancer-drug discovery and cardiovascular surveillance.
Groarke JD; Cheng S; Moslehi J
N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
[No Abstract] [Full Text] [Related]
15. Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Kamasani S; Akula S; Sivan SK; Manga V; Duyster J; Vudem DR; Kancha RK
Tumour Biol; 2017 May; 39(5):1010428317701643. PubMed ID: 28475010
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
17. Where exactly does ponatinib fit in chronic myelogenous leukemia?
Berman E
J Natl Compr Canc Netw; 2014 Nov; 12(11):1615-20. PubMed ID: 25361807
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
19. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
20. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.
Giudice V; Ghelli Luserna di Rorà A; Serio B; Guariglia R; Giannini MB; Ferrari A; Simonetti G; Selleri C; Martinelli G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
